Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C92579
http://purl.obolibrary.org/obo/NCIT_C92579
Preferred Name

Roniciclib
Definitions
An orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Roniciclib selectively binds to and inhibits the activity of CDK1/Cyclin B, CDK2/Cyclin E, CDK4/Cyclin D1, and CDK9/Cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle progression and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are often dysregulated in cancerous cells.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

An orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Roniciclib selectively binds to and inhibits the activity of CDK1/Cyclin B, CDK2/Cyclin E, CDK4/Cyclin D1, and CDK9/Cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle progression and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are often dysregulated in cancerous cells.
prefLabel
Roniciclib
label
Roniciclib
NCI_META_CUI
CL423828
PDQ_Closed_Trial_Search_ID
684718
code
C92579
Has_Target
prefixIRI
NCIT:C92579
in_subset
Display_Name
Roniciclib
Preferred_Name
Roniciclib
FDA_UNII_Code
0W9Q8U337A
Contributing_Source
CTRP
FDA
Maps_To
Roniciclib
CAS_Registry
1223498-69-8
NCI_Drug_Dictionary_ID
684718
type
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
684718
Semantic_Type
Pharmacologic Substance
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display